within Pharmacolibrary.Drugs.ATC.A;

model A16AB13
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 3.4999999999999995e-06,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A16AB13</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Asfotase alfa is a recombinant human tissue-nonspecific alkaline phosphatase enzyme replacement therapy indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP), a rare genetic disorder characterized by defective bone mineralization due to deficient activity of alkaline phosphatase. It is an approved medication for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in pediatric and adult patients with hypophosphatasia, based on population PK studies and summary data from clinical trials.</p><h4>References</h4><ol><li><p>Pan, WJ, et al., &amp; Seefried, L (2021). Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia. <i>Journal of clinical pharmacology</i> 61(10) 1334–1343. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1870&quot;>10.1002/jcph.1870</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33822385/&quot;>https://pubmed.ncbi.nlm.nih.gov/33822385</a></p></li><li><p>Dahir, KM, et al., &amp; Pan, WJ (2024). Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia. <i>Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</i> 39(10) 1412–1423. DOI:<a href=&quot;https://doi.org/10.1093/jbmr/zjae128&quot;>10.1093/jbmr/zjae128</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39135540/&quot;>https://pubmed.ncbi.nlm.nih.gov/39135540</a></p></li><li><p>Whyte, MP, et al., &amp; Landy, H (2012). Enzyme-replacement therapy in life-threatening hypophosphatasia. <i>The New England journal of medicine</i> 366(10) 904–913. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa1106173&quot;>10.1056/NEJMoa1106173</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22397652/&quot;>https://pubmed.ncbi.nlm.nih.gov/22397652</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A16AB13;
